VIDEO: Niraparib-ipilimumab maintenance prevents advanced pancreatic cancer progression
Click Here to Manage Email Alerts
In this video, Kim A. Reiss, MD, discussed the results of a randomized phase 1b/2 study of niraparib plus nivolumab or ipilimumab in patients with advanced pancreatic cancer, which were presented in a poster session at ASCO2022.
Maintenance with niraparib (Zejula, GlaxoSmithKine) plus ipilimumab (Yervoy, Bristol Myers Squibb) was effective in preventing progression in patients with advanced pancreatic cancer and led to a PFS of approximately 8 months, Reiss, assistant professor of medicine at the Hospital of the University of Pennsylvania, said. In comparison, niraparib plus nivolumab (Opdivo, Bristol Myers Squibb) was not effective in preventing progression, with an approximate PFS of 1.8 months, she said.
For this trial, 84 patients were randomized equally after discontinuation of chemotherapy.
"One of the important things that we wanted to look at was whether that response or efficacy in the niraparib plus ipilimumab arm might have been driven by patients with [DNA damage response]variants such as BRCA or PALB2, so we did some sub-analysis where we removed all of those patients from the analysis and, importantly, the PFS held up," Reiss said.
Collapse
Read more about
Click Here to Manage Email Alerts